Frigon L, Pascal JM*. Structural and biochemical analysis of the PARP1-homology region of PARP4/vault PARP. Nucleic Acids Res. 2023 Dec 11; 299(12): 105397.

​

Langelier MF, Lin X, Zha S, Pascal JM*. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA. Science Advances. 2023 Mar 24;9(12):eadf7175.

​

Kuttiyatveetil JRA, Soufari H, Dasovich M, Uribe IR, Mirhasan M, Cheng SJ, Leung AKL, Pascal JM*. Crystal structures and functional analysis of the ZnF5-WWE1-WWE2 region of PARP13/ZAP define a distinctive mode of engaging poly(ADP-ribose). Cell Reports. 2022 Oct 25;41(4):111529.

​

Rouleau-Turcotte É, Krastev DB, Pettitt SJ, Lord CJ, Pascal JM*. Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery. Molecular Cell. 2022 Aug 18;82(16):2939-2951.

​

Sverzhinsky A, Tomkinson AE, Pascal JM*. Cryo-EM structures and biochemical insights into heterotrimeric PCNA regulation of DNA ligase. Structure. 2022 Mar 3;30(3):371-385.

​

Zandarashvili L#, Langelier MF#, Velagapudi UK, Hancock MA, Steffen JD, Billur R, Hannan ZM, Wicks AJ, Krastev DB, Pettitt SJ, Lord CJ, Talele TT, Pascal JM*, and Black BE*. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020 Apr 3, 368(6486).

​

Langelier MF, Zandarashvili L, Aguiar PM, Black BE*, Pascal JM*. NAD(+) analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains. Nat Commun. 2018 Feb 27;9(1):844.

​

Eisemann T, McCauley M, Langelier MF, Gupta K, Roy S, Van Duyne GD, Pascal JM. Tankyrase-1 Ankyrin Repeats Form an Adaptable Binding Platform for Targets of ADP-Ribose Modification. Structure. 2016 Oct 4;24(10):1679-1692.

 

Steffen JD, McCauley MM, Pascal JM. Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage. Nucleic Acids Res. 2016 Nov 16;44(20):9771-9783.

​

Riccio AA, McCauley M, Langelier MF, Pascal JM. Tankyrase Sterile α Motif Domain Polymerization Is Required for Its Role in Wnt Signaling. Structure. 2016 Sep 6;24(9):1573-81.

 

Dawicki-McKenna JM#, Langelier MF#, DeNizio JE, Riccio AA, Cao CD, Karch KR, McCauley M, Steffen JD, Black BE*, Pascal JM*. PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain. Mol Cell. 2015 Dec 3;60(5):755-768.

 

Eustermann S, Wu WF, Langelier MF, Yang JC, Easton LE, Riccio AA, Pascal JM, Neuhaus D. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1. Mol Cell. 2015 Dec 3;60(5):742-754.

​

Langelier MF, Riccio AA, Pascal JM. PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res. 2014 Jul;42(12):7762-75.

 

Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD, Fronczek FR, Talele TT. Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors. J Med Chem. 2014 Jul 10;57(13):5579-601.

​

Steffen JD, Tholey RM, Langelier MF, Planck JL, Schiewer MJ, Lal S, Bildzukewicz NA, Yeo CJ, Knudsen KE, Brody JR, Pascal JM. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res. 2014 Jan 1;74(1):31-7.

​

Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science. 2012 May 11;336(6082):728-32.